# Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/pembrolizumab-plus-best-supportive-care-versus-placebo-plus-best-supportive-care/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Shukui Qin,Zhendong Chen,Weijia Fang,Zhenggang Ren,Ruocai Xu,Baek‐Yeol Ryoo,Zhiqiang Meng,Yuxian Bai,Xiaoming Chen,Xiufeng Liu,Juxiang Xiao,Gwo Fuang Ho,Yimin Mao,Xing Ye,Jieer Ying,Jianfeng Li,Wen Yan Zhong,Yu Zhou,Abby B. Siegel,Chunyi Hao |
| Citations | 111 |
| DOI | 10.1200/jco.2022.40.4_suppl.383 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4205155919 |
| Type | conference-abstract |
| Year | 2022 |

## Paper authors

- [Gwo Fuang Ho](https://scholariq.org/researchers/gwo-fuang-ho/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.